Fact Meets Function

Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue.

This human clinical study describes the treatment of Kleine-Levin Syndrome (a rare condition characterized by recurrent episodes of hypersomnia and behavioral changes) using intranasal photobiomodulation combined with methylene blue in individual patient cases. The report documents patient responses to this combined intervention approach, though specific efficacy data and outcome measures are not detailed in the provided information. As a human clinical case report or small series, this represents lower-level evidence compared to randomized controlled trials.

Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue. Read Post »

Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open-label randomized controlled clinical trial.

This open-label randomized controlled clinical trial (human clinical evidence) investigated whether methylene blue could reduce early postoperative cognitive dysfunction (POCD) in elderly patients undergoing major non-cardiac surgery. The study found that methylene blue treatment reduced the incidence of early POCD in this patient population compared to control. This represents direct clinical evidence from a human trial, though the open-label design (where participants and researchers knew treatment assignment) represents a moderate strength of evidence compared to blinded trials.

Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open-label randomized controlled clinical trial. Read Post »

An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease.

This human clinical study evaluated hydromethylthionine (a formulation of methylene blue) as a potential therapeutic agent for Alzheimer’s disease, examining its pharmacological properties and clinical efficacy based on available evidence. The research assessed hydromethylthionine’s mechanism of action, safety profile, and effectiveness in slowing cognitive decline in Alzheimer’s patients, contributing to the expert analysis of its role among treatment options. This evidence represents human clinical research on a pharmaceutical intervention for neurodegenerative disease.

An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease. Read Post »

Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.

This animal model study investigated whether the tripeptide-copper complex GHK-Cu (II) could improve healing outcomes following anterior cruciate ligament (ACL) reconstruction in rats, finding transient improvements in the healing process. The results demonstrated temporary benefits during the healing phase, though the study did not assess long-term functional outcomes. This is an **animal model study** (rat), not human clinical evidence despite the source tag designation.

Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Read Post »

Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement.

Research Summary

This human clinical study investigated plasma thymosin beta-4 (Tβ4) levels in chronic ischemic heart failure patients who received intracardiac cell therapy and found that increased plasma Tβ4 was associated with symptomatic improvement in these patients. The research suggests a potential biomarker relationship between Tβ4 elevation and clinical outcomes following cell-based cardiac intervention. This is human clinical-level evidence examining the mechanistic relationship between a circulating peptide and therapeutic response in heart failure patients.

Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement. Read Post »

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

This prospective, randomized, controlled study evaluated ipamorelin, a ghrelin mimetic, as a treatment for postoperative ileus in patients undergoing bowel resection. The research assessed whether ipamorelin could improve recovery of bowel function following surgery in this patient population. This evidence comes from a human clinical trial.

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Read Post »

Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.

Researchers analyzed serum peptide profiles in pregnant women to identify peptide biomarkers that could distinguish preeclampsia cases from normal pregnancies, utilizing peptidomic techniques to characterize protein fragments circulating in blood samples. The study identified specific peptide signatures, including TB4-Fragment, that showed potential diagnostic value for preeclampsia detection. This evidence comes from human clinical studies analyzing biomarker patterns in patient serum samples.

Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia. Read Post »

Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide.

This human clinical study examined how the tripeptide KPV (the C-terminal portion of alpha-melanocyte-stimulating hormone) affects corneal epithelial wound healing and the role of nitric oxide in this process. The research investigated the mechanisms by which KPV influences corneal epithelial cell repair, with particular focus on nitric oxide signaling pathways. This human clinical evidence provides direct data on KPV’s effects on corneal wound healing in human subjects.

Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Read Post »

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

This human clinical study examined whether pulsatile growth hormone secretion patterns persist when using CJC-1295, a long-acting growth hormone-releasing hormone analog, administered as continuous stimulation. The researchers found that pulsatile GH secretion was maintained despite the continuous nature of CJC-1295 stimulation, demonstrating that the body’s natural rhythmic GH release pattern is preserved with this compound. This evidence comes from a human clinical trial design.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Read Post »

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

This human clinical study examined CJC-1295, a long-acting GH-releasing hormone analog, and found that it stimulated prolonged secretion of growth hormone and insulin-like growth factor I in healthy adult subjects. The extended duration of hormone elevation distinguishes this compound from shorter-acting GH-releasing hormone preparations. This evidence comes from direct human clinical investigation.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Read Post »

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

This human clinical study developed a pharmacokinetic-pharmacodynamic model to characterize how ipamorelin, a growth hormone-releasing peptide, is absorbed, distributed, and produces effects in the body following administration to healthy volunteers. The modeling approach integrated drug concentration measurements with observed growth hormone responses to predict the relationship between ipamorelin dose and biological effect. This research provides quantitative data on ipamorelin’s time-concentration profile and growth hormone stimulation patterns in humans (human clinical evidence level).

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Read Post »

Scroll to Top